AUG 13, 2026 · PHASE 3 TRIAL
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
ClinicalTrials.gov
This is a Phase 3 RCT registration with no posted results; the study is actively recruiting and outcomes are not yet reported.
Reported
Planned sample size300
Randomization ratio1:1
Firmonertinib dose240 mg oral daily